Published in J Biol Chem on December 01, 2003
Remodeling of endothelial adherens junctions by Kaposi's sarcoma-associated herpesvirus. J Virol (2008) 1.15
Rho kinase: an important mediator of atherosclerosis and vascular disease. Curr Pharm Des (2009) 1.04
Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation (2016) 0.91
Apolipoprotein(a), through its strong lysine-binding site in KIV(10'), mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway. J Biol Chem (2008) 0.91
Lipoprotein(a) in cardiovascular diseases. Biomed Res Int (2012) 0.83
Lipoprotein(a): biology and clinical importance. Clin Biochem Rev (2004) 0.83
Lipoprotein(a): Cellular Effects and Molecular Mechanisms. Cholesterol (2012) 0.82
Activation of protein kinase C and disruption of endothelial monolayer integrity by sodium arsenite--Potential mechanism in the development of atherosclerosis. Toxicol Appl Pharmacol (2007) 0.80
Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? J Lipid Res (2015) 0.79
Apolipoprotein(a) acts as a chemorepellent to human vascular smooth muscle cells via integrin αVβ3 and RhoA/ROCK-mediated mechanisms. Int J Biochem Cell Biol (2013) 0.78
Current therapies for lowering lipoprotein (a). J Lipid Res (2015) 0.77
Apolipoprotein(a) stimulates nuclear translocation of β-catenin: a novel pathogenic mechanism for lipoprotein(a). Mol Biol Cell (2012) 0.76
Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA (2009) 5.63
Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab (2010) 3.29
Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia. J Clin Endocrinol Metab (2010) 2.70
A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol (2007) 2.47
Testing the accelerator hypothesis: body size, beta-cell function, and age at onset of type 1 (autoimmune) diabetes. Diabetes Care (2006) 2.26
Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation (2002) 2.17
Etiological approach to characterization of diabetes type: the SEARCH for Diabetes in Youth Study. Diabetes Care (2011) 2.15
C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int (2005) 2.13
Diabetes in non-Hispanic white youth: prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care (2009) 1.80
Diabetes in Hispanic American youth: prevalence, incidence, demographics, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care (2009) 1.78
Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem (2003) 1.74
Release of glutamate decarboxylase-65 into the circulation by injured pancreatic islet beta-cells. Endocrinology (2007) 1.61
Correlates of dietary intake in youth with diabetes: results from the SEARCH for diabetes in youth study. J Nutr Educ Behav (2011) 1.56
Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction. J Am Coll Cardiol (2012) 1.55
Type 1 and Type 2 diabetes in Asian and Pacific Islander U.S. youth: the SEARCH for Diabetes in Youth Study. Diabetes Care (2009) 1.52
The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care (2007) 1.44
Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. Am J Kidney Dis (2003) 1.42
Biomarkers related to severe hypoglycaemia and lack of good glycaemic control in ACCORD. Diabetologia (2015) 1.41
Higher prevalence of elevated albumin excretion in youth with type 2 than type 1 diabetes: the SEARCH for Diabetes in Youth study. Diabetes Care (2007) 1.38
High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol (2005) 1.29
Prevalence and determinants of elevated apolipoprotein B and dense low-density lipoprotein in youths with type 1 and type 2 diabetes. J Clin Endocrinol Metab (2007) 1.28
Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth. J Clin Endocrinol Metab (2013) 1.26
Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol (2013) 1.23
Signaling pathways regulating Dictyostelium myosin II. J Muscle Res Cell Motil (2002) 1.22
Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem (2004) 1.21
Serum C-reactive protein and leptin as predictors of kidney disease progression in the Modification of Diet in Renal Disease Study. Kidney Int (2002) 1.20
Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. Curr Opin Lipidol (2004) 1.20
Subclinical vitamin K deficiency in hemodialysis patients. Am J Kidney Dis (2007) 1.18
Association of type 1 diabetes with month of birth among U.S. youth: The SEARCH for Diabetes in Youth Study. Diabetes Care (2009) 1.17
Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation (2009) 1.16
PAK1 induces podosome formation in A7r5 vascular smooth muscle cells in a PAK-interacting exchange factor-dependent manner. Am J Physiol Cell Physiol (2005) 1.13
Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J (2006) 1.12
Inflammatory markers are increased in youth with type 1 diabetes: the SEARCH Case-Control study. J Clin Endocrinol Metab (2010) 1.12
Lipoprotein(a): a unique risk factor for cardiovascular disease. Clin Lab Med (2006) 1.12
Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: The Physicians' Health Study. Clin Chem (2004) 1.11
Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). J Am Coll Cardiol (2013) 1.10
Reduced heart rate variability among youth with type 1 diabetes: the SEARCH CVD study. Diabetes Care (2012) 1.08
Formation of extracellular matrix-digesting invadopodia by primary aortic smooth muscle cells. Circ Res (2007) 1.07
Lipoprotein(a): more interesting than ever after 50 years. Curr Opin Lipidol (2012) 1.06
Predicting memory decline in normal elderly: genetics, MRI, and cognitive reserve. Neurobiol Aging (2006) 1.05
Crystal structure of the alpha-kinase domain of Dictyostelium myosin heavy chain kinase A. Sci Signal (2010) 1.04
High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins. J Lipid Res (2005) 1.04
Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res (2013) 1.04
SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver. Mol Cell (2011) 1.03
An inducible propane monooxygenase is responsible for N-nitrosodimethylamine degradation by Rhodococcus sp. strain RHA1. Appl Environ Microbiol (2007) 1.01
Cardiovascular risk factors are associated with increased arterial stiffness in youth with type 1 diabetes: the SEARCH CVD study. Diabetes Care (2013) 1.01
Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol (2002) 1.00
Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study. J Lipid Res (2011) 1.00
Buffy coat specimens remain viable as a DNA source for highly multiplexed genome-wide genetic tests after long term storage. J Transl Med (2011) 1.00
Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem (2006) 1.00
Statins of different brain penetrability differentially affect CSF PLTP activity. Dement Geriatr Cogn Disord (2006) 1.00
Cellular distribution and functions of wild-type and constitutively activated Dictyostelium PakB. Mol Biol Cell (2004) 0.99
Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem (2003) 0.99
Autophosphorylation activates Dictyostelium myosin II heavy chain kinase A by providing a ligand for an allosteric binding site in the alpha-kinase domain. J Biol Chem (2010) 0.99
Plasma lipoprotein(a) indicates risk for 4 distinct forms of vascular disease. Clin Chem (2007) 0.98
Lamellipodial localization of Dictyostelium myosin heavy chain kinase A is mediated via F-actin binding by the coiled-coil domain. FEBS Lett (2002) 0.97
First WHO/IFCC International Reference Reagent for Lipoprotein(a) for Immunoassay--Lp(a) SRM 2B. Clin Chem Lab Med (2004) 0.97
Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol (2003) 0.96
Lipoprotein(a) enhances advanced atherosclerosis and vascular calcification in WHHL transgenic rabbits expressing human apolipoprotein(a). J Biol Chem (2002) 0.96
The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings. Metabolism (2005) 0.95
Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis. Blood (2007) 0.94
Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro. J Neurosci Res (2005) 0.93
Widespread distribution of PLTP in human CNS: evidence for PLTP synthesis by glia and neurons, and increased levels in Alzheimer's disease. J Lipid Res (2003) 0.93
Reduced heart rate variability is associated with increased arterial stiffness in youth with type 1 diabetes: the SEARCH CVD study. Diabetes Care (2013) 0.92
Small apolipoprotein(a) size predicts mortality in end-stage renal disease: The CHOICE study. Circulation (2002) 0.92
Sugar-sweetened and diet beverage consumption is associated with cardiovascular risk factor profile in youth with type 1 diabetes. Acta Diabetol (2011) 0.92
A myosin IK-Abp1-PakB circuit acts as a switch to regulate phagocytosis efficiency. Mol Biol Cell (2010) 0.92
Synthesis and SAR of novel benzoxaboroles as a new class of β-lactamase inhibitors. Bioorg Med Chem Lett (2011) 0.92
Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery. Bioorg Med Chem Lett (2011) 0.91
Determinants for substrate phosphorylation by Dictyostelium myosin II heavy chain kinases A and B and eukaryotic elongation factor-2 kinase. Biochim Biophys Acta (2008) 0.91
Apolipoprotein(a), through its strong lysine-binding site in KIV(10'), mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway. J Biol Chem (2008) 0.91
Differences in reactivity of antibodies to active versus inactive PLTP significantly impacts PLTP measurement. J Lipid Res (2002) 0.90
Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-Atherosclerosis Treatment Study (HATS). PLoS One (2013) 0.90
A role for CCAAT/enhancer-binding protein in hepatic expression of thrombin-activable fibrinolysis inhibitor. J Biol Chem (2002) 0.90
Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and β-cell function. Diabetes Care (2012) 0.89
Parental longevity and diabetes risk in the Diabetes Prevention Program. J Gerontol A Biol Sci Med Sci (2011) 0.89
Comparison of two insulin assays for first-phase insulin release in type 1 diabetes prediction and prevention studies. Clin Chim Acta (2011) 0.89
Determination of lipoprotein(a) kringle repeat number from genomic DNA: copy number variation genotyping using qPCR. J Lipid Res (2008) 0.89
Cardiovascular risk factors among youth with and without type 2 diabetes: differences and possible mechanisms. Diabetes Care (2008) 0.89
Identification of dimer interactions required for the catalytic activity of the TRPM7 alpha-kinase domain. Biochem J (2009) 0.88
The association between adiponectin/leptin ratio and diabetes type: the SEARCH for Diabetes in Youth Study. J Pediatr (2009) 0.88
7-ketocholesterol catabolism by Rhodococcus jostii RHA1. Appl Environ Microbiol (2009) 0.88
Apolipoprotein A1 and B. Clin Lab Med (2006) 0.87
Catalysis of covalent Lp(a) assembly: evidence for an extracellular enzyme activity that enhances disulfide bond formation. Biochemistry (2006) 0.87
A critical evaluation of the role of Lp(a) in cardiovascular disease: can Lp(a) be useful in risk assessment? Semin Vasc Med (2002) 0.87
Cardiovascular health in adolescents with type 1 diabetes: the SEARCH CVD study. Pediatr Diabetes (2014) 0.87
Lipoprotein(a) is associated differentially with carotid stenosis, occlusion, and total plaque area. Arterioscler Thromb Vasc Biol (2008) 0.86
Lipoprotein(a) metabolism. Curr Opin Lipidol (2014) 0.86
Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry. Bioorg Med Chem Lett (2008) 0.86
Correlates of medical nutrition therapy and cardiovascular outcomes in youth with type 1 diabetes. J Nutr Educ Behav (2013) 0.85
Identification and characterization of an 8-kDa light chain associated with Dictyostelium discoideum MyoB, a class I myosin. J Biol Chem (2006) 0.85
HLA-associated phenotypes in youth with autoimmune diabetes. Pediatr Diabetes (2012) 0.84